513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
RadNet reported third quarter 2024 revenue of $461.1 million, up 14.7%, and Adjusted EBITDA of $73.7 million, up 27.2%, with Adjusted diluted EPS of $0.18 versus $0.13. GAAP net income attributable to common stockholders fell to $3.2 million ($0.04 per diluted share) from $17.5 million ($0.25), and the company raised its Imaging Center revenue and Adjusted EBITDA guidance for 2024.
Q3 2024 Total Company Revenue was $461.1 million, up from $402.0 million; Adjusted EBITDA was $73.7 million, up from $57.9 million.
GAAP net income attributable to RadNet common stockholders was $3.2 million, or $0.04 per diluted share, versus $17.5 million, or $0.25, in Q3 2023; the company cited an $8.1 million non-cash loss from interest rate swaps among one-time ite
Adjusted diluted EPS was $0.18 versus $0.13 a year earlier.
Imaging Center 2024 guidance now projects Total Net Revenue of $1,710 - $1,760 million (up from $1,685 - $1,735 million) and Adjusted EBITDA of $262 - $270 million (up from $257 - $267 million).
Rocket Lab reported third-quarter 2024 results on November 12, 2024. Revenue rose 55% year over year to $104.8 million, but the net loss widened to $51.9 million from $40.6 million, and the adjusted EBITDA loss grew to $30.9 million from $15.5 million. The company guided fourth-quarter revenue to $125 million to $135 million, which it describes as a record quarter.
Q3 2024 revenue was $104.8 million, up from $67.7 million in Q3 2023.
Net loss was $51.9 million, or $0.10 per share, compared with $40.6 million, or $0.08 per share, a year earlier.
Q4 2024 guidance calls for revenue of $125 million to $135 million and GAAP gross margins of 26% to 28%.
CEO Sir Peter Beck cited a backlog of $1.05 billion.
Progyny reported third-quarter 2024 results on November 12, 2024. Revenue rose 2.0% to $286.6 million, but net income, gross margin and Adjusted EBITDA declined from a year earlier, and the company revised its full-year 2024 guidance lower. For shareholders, the revised outlook projects full-year 2024 revenue of $1.135 billion to $1.150 billion and net income of $49.9 million to $53.3 million, with the company citing unexpected variability in member treatment patterns.
Q3 2024 revenue rose 2.0% to $286.6 million, while net income fell to $10.4 million, or $0.11 per diluted share, from $15.9 million, or $0.16.
Gross margin fell to 20.7% from 22.3%, and Adjusted EBITDA was $46.5 million, down 7.1%.
Full-year 2024 revenue is now projected at $1.135 billion to $1.150 billion, and net income at $49.9 million to $53.3 million.
Fourth-quarter 2024 revenue is projected at $266.2 million to $281.2 million, or (1)% to 4% growth; a large client will not renew in 2025.
BioLife Solutions reported unaudited third-quarter 2024 revenue of $30.6 million, up 30% from a year earlier, and a GAAP net loss from continuing operations of $1.7 million, down from $15.8 million. The company also completed the $73.0 million cash sale of its SciSafe biostorage subsidiary on November 12, 2024, and cut its full-year 2024 total revenue guidance to $98.0 million to $100.0 million from $99.0 million to $101.0 million, citing the divestiture.
Q3 2024 total revenue was $30.6 million, up from $23.6 million in Q3 2023 and up 8% sequentially.
Q3 2024 GAAP net loss from continuing operations was $1.7 million, or $0.04 per share, versus $15.8 million, or $0.36 per share, a year earlier.
Adjusted EBITDA was $6.1 million, or 20% of revenue, compared with $1.4 million, or 6%, in Q3 2023.
Cell Processing 2024 revenue guidance was raised to $72.0 million to $73.0 million, while Biostorage Services guidance was lowered to $26.0 million to $27.0 million.
ICU Medical reported third quarter 2024 revenue of $589.1 million, up from $553.3 million a year earlier, but swung to a GAAP net loss of $33.0 million from net income of $7.2 million. The company also widened its full-year 2024 GAAP net loss outlook, while narrowing its adjusted EBITDA range, so shareholders face a mixed picture on reported results and updated guidance.
Q3 2024 revenue was $589.1 million, up from $553.3 million in Q3 2023.
GAAP net loss was $33.0 million, or $1.35 per diluted share, versus net income of $7.2 million, or $0.30 per share, a year earlier.
Adjusted diluted EPS was $1.59 versus $1.57, and adjusted EBITDA was $94.8 million versus $89.8 million.
FY2024 GAAP net loss outlook moved to $122 million to $130 million from $108 million to $118 million; adjusted EBITDA outlook is now $355 million to $365 million.
ZoomInfo reported third quarter 2024 results with GAAP revenue of $303.6 million, down 3% from a year earlier, and GAAP operating income of $43.5 million, down 31%. It raised its full-year 2024 adjusted net income per share guidance to $0.92-$0.93, from $0.86-$0.88 previously, while narrowing its full-year revenue guidance to $1.201-$1.204 billion.
Q3 2024 GAAP revenue was $303.6 million, down 3% year over year; GAAP diluted EPS was $0.07 versus $0.08 a year earlier.
Adjusted net income per share rose to $0.28 from $0.26, and adjusted operating income was $111.7 million, down 11%.
Full-year 2024 adjusted EPS guidance was raised to $0.92-$0.93; GAAP revenue guidance is $1.201-$1.204 billion, versus $1.190-$1.205 billion previously.
The company repurchased 24,478,696 shares for $242.1 million in the quarter, and has repurchased about 17% of outstanding shares since a buyback began in March 2023.
Life360 reported unaudited Q3 2024 total revenue of $92.9 million, up 18% year over year, and net income of $7.7 million, which the company said was helped by a one-time gain from investments and a tax benefit. It lowered its 2024 consolidated revenue guidance to $368 million-$374 million from $370 million-$378 million, citing lower hardware revenue, while raising its 2024 Adjusted EBITDA guidance to $39 million-$42 million from $36 million-$41 million.
Q3 2024 hardware revenue fell 24% year over year to $11.7 million, attributed to a delay in the new product launch.
2024 consolidated revenue guidance is $368 million-$374 million, down from $370 million-$378 million.
2024 Adjusted EBITDA guidance is $39 million-$42 million, up from $36 million-$41 million.
Q3 2024 net income was $7.7 million, including a $5.4 million gain on change in fair value of an investment; quarter-end cash was $160.2 million.
Perdoceo reported third-quarter 2024 revenue of $169.8 million, down 5.6% from the prior year quarter, and diluted EPS of $0.57 versus $0.62. The company raised its full-year 2024 outlook, with adjusted EPS now expected at $2.25 to $2.28, while revenue and reported EPS declined in the quarter.
Q3 2024 revenue $169.8 million, down 5.6%; year-to-date revenue $504.8 million, down 10.2%
Q3 diluted EPS $0.57 vs. $0.62; adjusted diluted EPS $0.59 vs. $0.64
Q3 operating income up 4.0% to $44.8 million; enrollments up 11.0% to 40,400
Full-year 2024 adjusted EPS outlook $2.25 to $2.28 vs. $2.10 in 2023; quarterly dividend of $0.13 per share payable December 13, 2024
Repligen reported third-quarter 2024 revenue of $155 million, up 10% from a year earlier, and narrowed its full-year 2024 revenue guidance to $630 million-$639 million while keeping the midpoint unchanged. GAAP results swung to a small loss, which the company attributed in part to $17.4 million of incremental stock compensation tied to the CEO's transition to Executive Chair, and the filing references a prior restatement of financial statements.
Q3 2024 revenue $155 million vs. $141 million in Q3 2023, up 10%
GAAP net loss of $0.7 million, or $0.01 per diluted share, vs. net income of $17 million, or $0.30 per share
Adjusted (non-GAAP) diluted EPS $0.43 vs. $0.23; includes $17.4 million of CEO transition stock compensation excluded from adjusted results
Schrödinger reported third-quarter 2024 total revenue of $35.3 million, down from $42.6 million a year earlier, while software revenue rose 10%. The net loss narrowed to $38.1 million from $62.0 million, mainly due to changes in the fair value of equity investments, and the company raised the low end of its 2024 software revenue growth guidance. The company also said Novartis will pay $150 million upfront under a new collaboration.
Total revenue fell 17% to $35.3 million; software revenue rose 10% to $31.9 million, while drug discovery revenue fell to $3.4 million from $13.7 million.
Software gross margin decreased to 73% from 76%; operating expenses rose to $86.2 million from $79.8 million.
2024 software revenue growth guidance is now 8% to 13%; drug discovery revenue guidance is $20 million to $30 million.
Novartis will pay Schrödinger $150 million upfront under a multi-target collaboration announced November 12, 2024.
Roivant reported results for the quarter ended September 30, 2024, with a net loss attributable to the company of $230.2 million, or $0.31 per share, compared with $304.3 million, or $0.40 per share, a year earlier. Net revenue rose to $4.5 million from $3.6 million, but general and administrative expenses rose to $202.9 million, including $79.1 million of one-time cash retention awards, and the non-GAAP loss from continuing operations widened to $218.7 million from $154.8 million.
Net loss attributable to Roivant was $230.2 million ($0.31 per share) vs. $304.3 million ($0.40 per share) a year earlier.
Revenue, net was $4.5 million vs. $3.6 million; R&D expenses were $143.1 million vs. $114.8 million.
G&A expenses were $202.9 million vs. $88.6 million, including $79.1 million of one-time cash retention awards approved in July 2024.
Cash, cash equivalents and marketable securities were approximately $5.4 billion at September 30, 2024, after $106 million of share repurchases in the quarter.
Mosaic reported third-quarter 2024 net income of $122 million, or $0.38 per diluted share, compared with a net loss of $4 million a year earlier, but revenue fell 21% to $2.8 billion on lower selling prices and adjusted EBITDA dropped to $448 million from $594 million. The company also said CFO Clint Freeland will retire, with Luciano Siani Pires succeeding him as chief financial officer on January 1, 2025.
Q3 2024 net income $122 million ($0.38 per diluted share) vs. net loss of $4 million in Q3 2023; adjusted EPS $0.34 vs. $0.68 a year earlier
Revenue $2.8 billion, down 21% from the year-ago period; adjusted EBITDA $448 million vs. $594 million
Clint Freeland to retire; Luciano Siani Pires joins as CFO designate November 18, 2024 and becomes CFO January 1, 2025
Year-to-date capital return of $415 million, including $210 million of share repurchases
Assured Guaranty reported third quarter 2024 GAAP net income of $171 million, or $3.17 per diluted share, up from $157 million, or $2.60, a year earlier. Adjusted operating income, the measure management uses for its core results, fell to $130 million, or $2.42 per share, from $206 million, or $3.42, partly because the 2023 period included a $241 million pre-tax gain from the Sound Point and AHP transactions.
GAAP net income was $171 million, or $3.17 per diluted share, for Q3 2024, versus $157 million, or $2.60, for Q3 2023; the company cited a $54 million foreign exchange gain among pre-tax adjustments.
Adjusted operating income was $130 million, or $2.42 per share, versus $206 million, or $3.42, in Q3 2023.
Q3 2024 capital returned to shareholders totaled $147 million, including $131 million of share repurchases and $16 million of dividends.
On November 8, 2024, the board authorized an additional $250 million of share repurchases; about $385 million remained authorized as of that date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.